首页 > 期刊杂志 > 正文

Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases.

胆管导管内管状乳头状肿瘤:20例临床病理、免疫组化及分子分析

Schlitter AM,Jang KT,Klöppel G,Saka B,Hong SM,Choi H,Offerhaus GJ,Hruban RH,Zen Y,Konukiewitz B,Regel I,Allgäuer M,Balci S,Basturk O,Reid MD,Esposito I,Adsay V

Abstract

Intraductal tubulopapillary neoplasm is a well-established entity in the pancreas. A similar, if not identical, tumor occurs also in the biliary tract. We conducted a multicenter study of 20 such lesions, focusing on their clinicopathologic characteristics and molecular profile. Biliary intraductal tubulopapillary neoplasms were seen in patients in their 60s (mean 62 years). The tumors were intrahepatic 70%, extrahepatic 10%, and perihilar 20%; mean tumor size was 6.9 cm. Histologically, all intraductal tubulopapillary neoplasms showed, in addition to their typical tubular pattern, solid areas (70%) or abortive papillae (50%). Necrosis was common (85%), predominantly focal (40%), and with 'comedocarcinoma-like pattern' in 40%. Immunohistochemically, these neoplasms were characterized by the expression of MUC1 (80%) and MUC6 (30%) and by the absence of MUC2 and MUC5AC. Associated invasive carcinomas were present in 16 (80%), mainly conventional tubular adenocarcinoma (50%). The molecular alterations observed included CDKN2A/p16 (intraductal components 44%, invasive 33%) and TP53 (intraductal components 17%, invasive 9%). Mutations in KRAS (intraductal 6%, invasive 0%), PIK3CA (intraductal 6%, invasive 0%), and loss of SMAD4/DPC4 (intraductal 7%, invasive 0%) were rare. No alterations/mutations were identified in IDH1/2, BRAF, GNAS, EGFR, HER2, and β-catenin. Follow-up information was available for 17 patients (85%) with mean follow-up 44 months. Overall combined survival rates showed favorable prognosis: 1 year 100%, 3 years 90%, and 5 years 90%. In conclusion, despite the relatively high incidence of invasive carcinoma (80%), available follow-up suggests that biliary intraductal tubulopapillary neoplasms have an indolent behavior. Molecular analyses highlight the low prevalence of alterations of common oncogenic signaling pathways in intraductal tubulopapillary neoplasm. Further studies using whole-exome sequencing are required to discover yet unknown molecular changes and to understand the carcinogenesis of intraductal tubulopapillary neoplasms.

摘要

导管内管状乳头状肿瘤是胰腺中好发且已有共识的一种肿瘤亚型。胆道中也发生与此类似但不相同的肿瘤。我们对20例这样的病变进行多中心研究,重点关注其临床病理特征和分子特点。胆道导管内管状乳头状肿瘤见于六十多岁的病人(平均年龄62岁),肿瘤发生部位:肝内占70%、肝外占10%、肝门周围占20%,肿瘤平均大小为6.9厘米。组织学方面,除了典型的管状结构,所有的导管内管状乳头状肿瘤显示有实性区域(70%)或流产型乳头结构(50%)。坏死常见(85%),主要呈灶状(40%),40%的坏死呈粉刺癌样模式。免疫组化染色,肿瘤表达MUC1(80%)和MUC6(30%),不表达MUC2和MUC5AC。其中有16例(80%)伴浸润性癌,后者主要是普通型管状腺癌(50%)。分子改变包括CDKN2A/p16 (导管内成分44%,浸润性成分33%)和TP53 (导管内成分17%,浸润性成分9%)。KRAS(导管内成分6%,浸润性成分0%)和PIK3CA(导管内成分6%,浸润性0%)的突变以及SMAD4/DPC4 (导管内成分7%,浸润性成分0%)的缺失很少见。未发现IDH1/2、BRAF、GNAS、EGFR、HER2和β-catenin改变/突变。随访17名病人(85%),平均随访时间为44个月。总体联合生存显示预后好:1年100%、3年90%、5年90%。结论:尽管浸润性癌的发生率相对较高(80%),随访结果提示胆道导管内管状乳头状肿瘤生物学行为惰性。分子分析显示导管内管状乳头状肿瘤中常见致癌信号通路改变的发生率较低。目前需要采用全基因组测序方法深入研究、发现仍然未知的分子改变,帮助我们理解导管内管状乳头状肿瘤的致癌作用。

full text

我要评论

0条评论